CONFERENCE SPEAKERS

Speakers
Christine Rothe
Christine Rothe
CDO,
iOmx Therapeutics AG


Philip Arlen
Philip Arlen
Chief Executive Officer,
Precision Biologics


Tomasz Grabowski
Tomasz Grabowski
Head of Preclinical Development,
JJP Biologics


Holger Weber
Holger Weber
Head of In Vivo Pharmacology,
Reaction Biology Europe GmbH


Jens Kringelum
Jens Kringelum
VP, AI & Innovation,
Evaxion Biotech


Adriana Turqueti Neves
Adriana Turqueti Neves
Associate Director,
iOmx Therapeutics AG


Sarah-Kim Friedrich-Becker
Sarah-Kim Friedrich-Becker
Senior Principal Scientist,
Abalos Therapeutics GmbH


Eric Halioua
Eric Halioua
President & Chief Executive Officer,
PDC*line pharma SA

Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with his different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, Eric has raised as of now a total of more than €170 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is CEO of the biotechnology company PDC*line Pharma and board member of Essenscia (Bio.be). Eric is co-founder of four biotechnology companies called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric worked for 12 years in the Healthcare and Life Sciences Practice of Arthur D. Little. Eric holds two master’s degrees in pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.


Rick Kamps
Rick Kamps
NGS Manager,
Maastricht University

Currently, Dr. Rick Kamps is working as a Laboratory Manager in the Department of Toxicogenomics and as a teacher supervising many Bachelor students in the concept of Problem Based Learning (PBL) in the Faculty of Health, Medicine, and Life Sciences since 2010. Furthermore, he has more than 25 years of research experience in the diagnostics and biotechnology sector (e.g., Academic Hospitals in Aachen (Germany) and Maastricht (the Netherlands), and Philips Research Eindhoven (the Netherlands).  He is more than a decade skilled in Next-generation sequencing in multiple applications (e.g., RNA/DNA sequencing). At the end of 2020, he gained a Ph.D. in Resolving the Role of Genetic Defects and the Mitochondrial DNA Copy Number in Mitochondrial Disease and Embryonic Development.


Despina Stefanoska
Despina Stefanoska
Business Development Manager,
Biognosys


Eike Staub
Eike Staub
Head of Oncology Data Science,
Merck Healthcare, Germany

Dr. Eike Staub started his bioinformatics career as a Ph.D. student in one of the first oncogenomic drug hunting companies,  metaGen in Berlin. After a short academic research phase focusing on evolution of protein families and genome content in the post-human genome era as a group lead in the Computational Biology group at the Max Planck Institute for Molecular Genetics in Berlin, he joined Altana Pharma to continue working on oncogenomics for drug research. In 2007 Eike joined Merck KGaA where he worked in various functions to leverage genome-scale data by bioinformatics algorithms, biostatistics, data mining & machine learning for oncology, from identification of drug targets to biomarker assessment in late clinical drug development.

Since 2015 he has been leading Oncology Bioinformatics in the Translational Medicine department at Merck KGaA, a team that is responsible for genome-scale data analysis from early pre-clinical research to late stage clinical development. His team is also committed to  deliver computational infrastructure to enable Merck scientist to conduct biomarker research using self-service tools.


Raj Mehta
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics Ltd

Raj is a serial entrepreneur with passion for identifying, nurturing and launching spin-out companies with over 20 years track record of building lasting partnerships.
Raj currently serves as CEO and NED of Adendra Therapeutics, a company he co-Founded as Entrepreneur in Residence at Apple Tree Partners (ATP). Raj is also co-founder and serves on the board of Revitope Oncology and on SAB of Hawk Biosystems.

He joined ATP from GammaDelta Therapeutics – a company he co-founded, served as interim CEO, board member and latterly as Director of Business Development. At GammaDelta, Raj led the efforts to raise >$100M, establish innovative partnership with Takeda Pharmaceutical Company, acquisition of Lymphact and spinning out of Adaptate Biotherapeutics. Takeda subsequently acquired both GammaDelta and Adaptate. 

Prior to GammaDelta Therapeutics, Raj spent over 18 years at Cancer Research Technology (CRT) where he served in a variety of leadership roles. Whilst at CRT, Raj founded and served as interim CEO/NED of BliNK Therapeutics


Elie Peillon
Elie Peillon
Associate Director Marketing,
Veracyte


Frank Jaschinski
Frank Jaschinski
CSO,
Secarna Pharmaceuticals


Eytan Breman, Director
Eytan Breman, Director
Research & Development,
Celyad Oncology


Jean-Luc Henrioul
Jean-Luc Henrioul
Chief Operating Officer,
Seqalis


Daniel Crowley
Daniel Crowley
CEO,
RemedyBio


Senior Representative, Veracyte
Senior Representative, Veracyte
,


Anamarija Pfeiffer
Anamarija Pfeiffer
Senior Scientific Project Manager,
Biognosys


Marine Blackman
Marine Blackman
Research Scientist,
Celyad Oncology


Philipp Wortmann
Philipp Wortmann
Director, Translational Science,
Astrazeneca


Jinyu Shan
Jinyu Shan
Professor,
University of Leicester